Effect of Statin Therapy on the Carboxypeptidase U (CPU, TAFIa, CPB2) System in Patients With Hyperlipidemia: A Proof-of-concept Observational Study

This publication has 22 references indexed in Scilit:

• Structure‐function relationships in thrombin‐activatable fibrinolysis inhibitor
  Journal of Thrombosis and Haemostasis, 2016
• An update on the role of carboxypeptidase U (TAFIa) in fibrinolysis
  Frontiers in Bioscience-Landmark, 2011
• Effect of statin therapy on colorectal cancer
  Gut, 2010
• Development of a sensitive and selective assay for the determination of procarboxypeptidase U (thrombin-activatable fibrinolysis inhibitor) in plasma
  Analytical Biochemistry, 2010
• Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study
  Journal of Thrombosis and Haemostasis, 2008
• Statins and C‐Reactive Protein Levels
  The Journal of Clinical Hypertension, 2007
• Effect of atorvastatin on different fibrinolyis mechanisms in hypercholesterolemic subjects
  International Journal of Cardiology, 2004
• Effects of HMG-CoA Reductase Inhibitors on Coagulation and Fibrinolysis Processes
  Drugs, 2003
• Fluvastin therapy affects TAFI concentration in kidney transplant recipients
  Transplant International, 2003
• Purification and characterization of a new arginine carboxypeptidase in human serum
  Biochimica et Biophysica Acta (BBA) - General Subjects, 1990